EUCTR2016-004110-10-PL进行中（未招募）1 期
Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The therapeutic potential of mesenchymal stem cells tested in clinical trials and in vitro - a justification for characterized cells storage'.
Medical University of Warsaw0 个研究点目标入组 100 人开始时间: 2017年5月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age 18 - 75 years at the time of qualification to the study
- •2.Signing informed consent form
- •3.Women / men
- •4.Scar or cutis laxa
- •a.Scar eligibility conditions:
- •Chest and neck
- •Onset time: over 6 months
- •Scars previously untreated
- •Atrophic and hypertrophic scars
- •Two scars in close location, each from 2 to 6 cm long and a total surface area of 1 sq. cm to 5 sq. cm or single scar of 8 to 16 cm long and a surface area of 1 to 5 sq.cm or a selected fragment of a scar of a surface area of 1 to 5 sq.cm in case of a scar's surface area bigger than 5 sq.cm.
- •b.Cutis laxa eligibility conditions:
- •Vast sun discoloration.
- •Pigmentation changes areas.
- •Solar stains.
- •Pigment changes also called age spots.
- •Cracked blood vessels.
- •Ruby nevus.
- •Atrophic changes of the skin and subcutaneous tissue
- •Changes symmetrically present on both hands
- •5.Without previous aesthetic treatment in this area, previous standard care.
- •6.Patient's health which allows anesthesia for liposuction.
- •7.Ready for follow-up visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1.Active cancer (diagnosed during past 5 years), excluding cured non-melanoma skin cancer or other non-invasive or in situ cancer (eg. cervical cancer)
- •2.Active chronic infection
- •3. Chronic use of NSAIDs
- •4.Taking any anticoagulant by the patient during 1 hour prior to surgery (excluding prophylactic heparin before liposuction).
- •5.Coagulation disorders in medical history and actual test results out of normal ranges.
- •6.Skin infections.
- •7.Allergies to medications used during liposuction (eg. Lidocaine and derivatives).
- •8.Status post radiotherapy or chemotherapy
- •9.Any other disease or condition that may change the evaluation of skin condition (eg. autoimmune disease of the connective tissue)
- •10.Taking the corticosteroid drugs or cytotoxic medications during the past 30 days
- •11.Allergy to materials of animal origin
- •12.Diagnosis of diabetes Type I
- •13.Diagnosis of AIDS, HBV or HCV (positive laboratory test result)
- •14.Hirsutism or a tattoo at the treatment site
- •15.Insufficient fat tissue for fat donation
- •16.Scar after removal of cancer.
- •17.The patient does not qualify to participate in this study in the opinion of the investigator
- •18.Pregnancy, breast feeding.
- •19.Photoallergy or using the drugs causing photoallergy.
- •20.Active herpes
- •21.Idiopathic keloids
- •22.Esthetic or medicinal treatments done previously at the treatment site
- •23.The use of derivatives of vitamin A during 6 months before the treatment
- •24.Fitzpatric phototype V and VI
- •25.Patients with mental disorders or addicted to drugs and/or alcohol.
- •26.Participation in other clinical study during the past 6 months.
- •27.Reactive result of serological and viral tests (ie. HIV-1 and 2 (HIV Ag / Ab)
- •Hepatitis B Virus Infection, – HbsAg and Anti-HBc;
- •Hepatitis C Virus Infection, Anti-HCV;
- •Syphilis specific tests
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: Therapeutic potential of adipose-derived stem cells, proven in clinical trials and examined in vitro - rationale for banking of well characterized cells”MedDRA version: 20.0 Level: LLT Classification code 10012664 Term: Diabetic foot ulcer System Organ Class: 100000004858Diabetic foot ulcerEUCTR2016-004109-15-PLMedical University of Warsaw50
进行中（未招募）
1 期
Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)MedDRA version: 18.0Level: LLTClassification code 10048043Term: WrinklingSystem Organ Class: 100000004858EUCTR2014-001815-38-DEAllergan Limited750
进行中（未招募）
1 期
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown LinesFacial Rhytides (Forehead Lines, Glabellar Lines)MedDRA version: 18.1Level: LLTClassification code 10048043Term: WrinklingSystem Organ Class: 100000004858EUCTR2014-001860-36-IEAllergan Limited400
进行中（未招募）
1 期
Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)MedDRA version: 17.0Level: LLTClassification code 10048043Term: WrinklingSystem Organ Class: 100000004858EUCTR2014-001815-38-BEAllergan Limited750
进行中（未招募）
1 期
Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)MedDRA version: 18.0Level: LLTClassification code 10048043Term: WrinklingSystem Organ Class: 100000004858EUCTR2014-001815-38-GBAllergan Limited750